Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies-an update
- 1 January 2000
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (1) , 167-171
- https://doi.org/10.1517/13543784.9.1.167
Abstract
In the past few years there has been significant progress in the development of therapy for the treatment of relapsing remitting and secondary progressive multiple sclerosis. Research interest in multiple sclerosis (MS) therapeutics has remained high and clinical investigation into potential new therapies continues. This review summarises the advances with currently available therapies and briefly outlines the results from studies with other drugs being developed for the treatment of multiple sclerosis.Keywords
This publication has 4 references indexed in Scilit:
- The effect of anti-α4 integrin antibody on brain lesion activity in MSNeurology, 1999
- A Double‐Blind, Placebo‐Controlled, Randomized Trial of Cladribine in Relpaasing‐Remitting Multiple SclerosisProceedings of the Association of American Physicians, 1999
- TreatmentsMultiple Sclerosis Journal, 1998
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisPublished by Elsevier